Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity

N Engl J Med. 2022 Mar 3;386(9):892-894. doi: 10.1056/NEJMc2112186.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Clinical Trial, Phase III
  • Letter
  • Randomized Controlled Trial

MeSH terms

  • Antibodies, Monoclonal, Humanized / adverse effects
  • Antibodies, Monoclonal, Humanized / pharmacokinetics
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Antiviral Agents / adverse effects
  • Antiviral Agents / pharmacokinetics
  • Antiviral Agents / therapeutic use*
  • Chronic Disease
  • Heart Diseases / complications
  • Humans
  • Infant
  • Infant, Newborn
  • Infant, Premature*
  • Infant, Premature, Diseases / prevention & control*
  • Injections, Intramuscular
  • Lung Diseases / complications
  • Palivizumab / therapeutic use
  • Respiratory Syncytial Virus Infections / complications
  • Respiratory Syncytial Virus Infections / prevention & control*

Substances

  • Antibodies, Monoclonal, Humanized
  • Antiviral Agents
  • Palivizumab
  • nirsevimab

Associated data

  • ClinicalTrials.gov/NCT03959488